Back to News
Market Impact: 0.28
Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases
Source: Business Wire
Private Markets & VentureHealthcare & BiotechProduct Launches
Moonwalk Biosciences announced a $70 million Series B financing to advance adipose-targeted RNAi therapies for obesity and cardiometabolic diseases. The funding is a positive validation of the company’s therapeutic platform and supports further development in a large, competitive metabolic-disease market, though it is unlikely to have broad public-market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Scalpers offer Apple iPhone Duo buyers hundreds extra outside Beijing launch
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- OpenAI Targets $1.25 Trillion Valuation in New Funding Round
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Selecting an AI Research Platform for Institutional Investors
- Weekly Update: New Reporting Features and More Sources for Document Search